drugset / Trial / NCT05877872
Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3
Recruiting
424 enrolled
Sun Yat-sen University
Fifth Affiliated Hospital of Guangzhou Medical University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabFirst People's Hospital of Foshan · collabNanfang Hospital, Southern Medical University · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to compare efficacy of two different resection extension in patients with resectable recurrent nasopharyngeal carcinoma after induction chemotherapy. The main question it aims to answer is that whether tumor regress areas after induction chemotherapy required complete resection. Patients will be randomly assigned to receive reduced-target resection or full-target resection after induction chemotherapy. Researchers will compare these two groups to see if the efficacy of reduced-target resection is not inferior to full-target resection.
Timeline
- Start
- 2023-05-20
- Primary completion
- 2029-03-30
- Completion
- 2029-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Toripalimab | Monoclonal antibody | 240 mg | — |